Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial (vol 31, pg 2477, 2013)

被引：0

作者：

Siu, L. L.

Shapiro, J. D.

Jonker, D. J.

机构：

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 18期

关键词：

D O I：

10.1200/JCO.2015.62.8701

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2124 / 2124

页数：1

共 9 条

[1] Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
Siu, Lillian L.
Shapiro, Jeremy D.
Jonker, Derek J.
Karapetis, Chris S.
Zalcberg, John R.
Simes, John
Couture, Felix
Moore, Malcolm J.
Price, Timothy J.
Siddiqui, Jehan
Nott, Louise M.
Charpentier, Danielle
Liauw, Winston
Sawyer, Michael B.
Jefford, Michael
Magoski, Nadine M.
Haydon, Andrew
Walters, Ian
Ringash, Jolie
Tu, Dongsheng
O'Callaghan, Chris J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) : 2477 - 2484
[2] Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial
Siu, Lillian L.
Shapiro, Jeremy David
Jonker, Derek J.
Karapetis, Christos Stelios
Zalcberg, John Raymond
Simes, John
Couture, Felix
Moore, Malcolm J.
Price, Timothy Jay
Siddiqui, Jehan
Nott, Louise M.
Charpentier, Danielle
Liauw, Winston S.
Sawyer, Michael B.
Jefford, Michael
Magoski, Nadine M.
Haydon, Andrew Mark
Walters, Ian B.
Tu, Dongsheng
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO. 20 trial.
Siu, Lillian L.
Shapiro, Jeremy D.
Jonker, Derek J.
Karapetis, Christos Stelios
Zalcberg, John Raymond
Simes, John
Couture, Felix
Moore, Malcolm J.
Price, Timothy Jay
Siddiqui, Jehan
Nott, Louise M.
Charpentier, Danielle
Liauw, Winston S.
Sawyer, Michael B.
Jefford, Michael
Magoski, Nadine M.
Haydon, Andrew Mark
Walters, Ian B.
Tu, Dongsheng
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[4] A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.
Shapiro, J. D.
Siu, L. L.
Zalcberg, J. R.
Moore, M. J.
Ringash, J.
Mittmann, N.
Simes, J.
O'Callaghan, C. J.
Tu, D.
Walters, I. B.
Magoski, N.
Smith, P.
Nomikos, D.
Zhu, L.
Savoie, M.
Virk, S.
El-Tahche, F.
Gill, R.
Price, T. J.
Jonker, D. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5] Quality of life (QoL) assessment in patients (pts) with K-RAS wild-type (WT) chemotherapy refractory metastatic colorectal cancer (mCRC) treated with cetuximab (CET) plus brivanib alaninate (BRIV) or placebo: Results of the NCIC Clinical Trials Group and AGITG CO.20 trial.
Ringash, Jolie
Au, Heather-Jane
Siu, Lillian L.
Shapiro, Jeremy D.
Jonker, Derek J.
Zalcberg, John Raymond
Moore, Malcolm J.
Strickland, Andrew H.
Kotb, Rami
Jeffery, Mark
Alcindor, Thierry
Ng, Siobhan
Salim, Muhammad
Sabesan, Sabe S.
Easaw, Jacob C.
Shannon, Jennifer Anne
El-Tahche, Fabyolla
Walters, Ian B.
Tu, Dongsheng
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[6] Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)
Tsuji, A.
Eto, T.
Masuishi, T.
Satake, H.
Segawa, Y.
Tanioka, H.
Hara, H.
Kotaka, M.
Sagawa, T.
Watanabe, T.
Nakamura, M.
Takahashi, T.
Negoro, Y.
Manaka, D.
Fujita, H.
Suto, T.
Ichikawa, W.
Fujii, M.
Takeuchi, M.
Nakajima, T.
ANNALS OF ONCOLOGY, 2016, 27
[7] High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC)
Jonker, D. J.
Karapetis, C.
Harbison, C.
O'Callaghan, C. J.
Tu, D.
Simes, R. J.
Xu, L.
Moore, M. J.
Zalcberg, J. R.
Khambata-Ford, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[8] The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).
Jonker, Derek J.
Nott, Louise M.
Yoshino, Takayuki
Li, Chiang
Gill, Shariene
Shapiro, Jeremy David
Ohtsu, Atsushl
Zalcberg, John Raymond
Vickers, Michael M.
Slims, John
Wei, Alice Chia-Chi
Mittmann, Nicole
Magoski, Nadine M.
Murray, Yvonne
Tsobanis, Eric
Tu, Dongsheng
Kerstein, David
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[9] Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
Qin, Shukui
Li, Jin
Wang, Liwei
Xu, Jianming
Cheng, Ying
Bai, Yuxian
Li, Wei
Xu, Nong
Lin, Li-zhu
Wu, Qiong
Li, Yunfeng
Yang, Jianwei
Pan, Hongming
Ouyang, Xuenong
Qiu, Wensheng
Wu, Kaichun
Xiong, Jianping
Dai, Guanghai
Liang, Houjie
Hu, Chunhong
Zhang, Jun
Tao, Min
Yao, Qiang
Wang, Junyuan
Chen, Jiongjie
Eggleton, S. Peter
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) : 3031 - +

← 1 →